Navigation Links
Vium Enhances Roster of Senior Leaders With Key Hires And Strategic Promotion of Chief Scientific Officer

Vium, Inc., the leading innovator for in vivo research utilizing its state-of-the-art Digital Vivarium™ and Vium Cloud approach to accelerate preclinical drug discovery and development, today announced the promotion of Laura Schaevitz, Ph.D., to Chief Scientific Officer. Additionally, the company announced the appointment of Jeff Caron to the newly formed role of Senior Vice President of Engineering and Ted Ira to Vice President of Sales.

“I am pleased to announce the promotion of Dr. Schaevitz who has been a crucial member of the Vium team for more than three years. She has played an integral role in building Vium’s in vivo drug testing platform into a world leading technology that is improving data insights and advancing drugs to clinical trials,” said Vium President and CEO Wendel Barr. “As we continue to grow and innovate as a company, we are pleased to welcome Ted and Jeff to the Vium leadership team. We believe that Jeff’s precision health technology and engineering background and Ted’s significant pharmaceutical and contract research sales and sales leadership experience will be invaluable as we continue to advance our Digital Vivarium technology to deliver breakthrough accuracy and speed in preclinical testing.”

Dr. Schaevitz has more than 20 years of experience with in vivo animal studies and has a proven track record in utilizing a broad spectrum of mouse models including transgenic models including autism, schizophrenia, Rett syndrome, and blindsight. Formerly Vice President of Scientific Technologies for Vium, she now oversees the development of Vium’s scientific program drawing upon her experiences as a molecular and behavioral neuroscientist to direct the application of Vium’s digital metrics to animal models across therapeutic areas including respiratory and inflammatory diseases.

She and her team work to enable pharmaceutical and biotechnology companies to conduct effective animal studies with predictive, continuous digital data that allows life science companies to better identify and prioritize lead compounds for further investigation. Dr. Schaevitz received her Ph.D. in Neuroscience at Stanford University in 2006.

Jeff Caron joined the company as the lead digital technology executive with experience in delivering secure solution architecture and innovative healthcare and life sciences solutions. Prior to joining Vium, Caron was vice president, software engineering and chief architect at GE Healthcare where he grew the GE Life Science Digital organization to include two global engineering centers of excellence (COEs) that focused on digital solutions for drug discovery, process development, manufacturing, clinical trials decision support, and AI-driven diagnostics. Previously, Caron worked at Microsoft where he led the development of data aggregation and analytics enterprise and cloud-based platforms enabling real-time patient monitoring and population health.

Caron holds patents in methods that analyze images leveraging quantitative assays, and algorithmic techniques for diagnostics and clinical interpretation. He received his Computer Science, Mathematics degree (specialization in advanced image analysis and visualization) from Concordia University in Montreal, Canada.

Ted Ira brings more than 20 years of senior level sales and business development experience in the bioscience and health services field to Vium. Prior to joining the company, Ira was the executive director of business development for SRI International where he led the drug discovery, development, and innovative platform commercial efforts for the Biosciences division. Previously, Ira held various senior sales roles at Covance in support of its preclinical services business. Ira received a BS in Natural Resources from the University of Michigan and an MBA from the University of San Francisco.

About Vium, Inc.

Vium is the first company to create a living informatics platform for preclinical in vivo drug research. The Vium Digital Vivarium™, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible. Vium is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the ‘3 Rs’, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical and computational drug discovery companies, academia, and novel therapeutic labs. Vium is backed by leading investors, including Lux Capital, Data Collective, Dolby Family Ventures, AME Cloud Ventures, Founders Fund, and Future Shape LLC. Vium is headquartered in San Mateo, California.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology technology :

1. Enhances User Experience with Site Re-launch concentrating on Pipettes, Pipette Tips and ISO 17015 Pipette Calibration Service
2. AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App
3. SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS)
4. Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters
5. CD-adapco’s New DARS v2.10 Release Enhances User Capabilities
6. Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems
7. Vaccinogen Enhances Patient-Derived Antibody Program with Revolutionary High-Throughput Single Cell Screening and Analysis System
8. SpineFrontier Enhances the MISquito Percutaneous Pedicle Screw System in Response to Growing Demand
9. Intelica CRE Enhances Services To Grow St. Louis Business
10. Exxact Corporation Enhances Its Deep Learning Portfolio with NVIDIA DGX Station and DGX-1
11. 5W Public Relations Expands Corporate Practice, Adds PURE Bioscience, Inc. to Client Roster
Post Your Comments:
(Date:6/26/2019)... VEGAS (PRWEB) , ... June 26, 2019 , ... Alice ... energy treatment on improving physicochemical properties of Magnesium Gluconate, which can prove to be ... Over 125% alteration of characteristic differentiation peak, change in crystallite size , ...
(Date:6/18/2019)... ... June 18, 2019 , ... Personalized Stem Cells, Inc ... (IND) application to the FDA for use of a person’s own adipose-derived stem cells ... of osteoarthritis in the knee. This IND is the first of several planned ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... distribution network with the appointment of Biofeedback Tech Ltd as its ... are an essential part of many therapeutic treatments and clinical assessment protocols to ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... will add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed ... DeepDyve’s continually expanding library of more than 20 million articles, sourced from more ...
Breaking Biology Technology:
(Date:7/19/2019)... Calif. (PRWEB) , ... July 18, 2019 , ... ... clinical, regulatory and manufacturing experience. As a result of a two-year research ... commercialize the Calidi oncolytic virus platform in veterinary medicine. VetStem should be able ...
(Date:7/17/2019)... (PRWEB) , ... July 16, 2019 , ... At nearly ... his back legs. According to his owner, in the last year or so, ... under him. His veterinarian, Dr. Cindy Echevarria of VCA University Animal Hospital ...
(Date:7/9/2019)... ... 2019 , ... KMK Consulting, Inc. announced the ... expansion strengthens KMK’s presence for the sales, support, and delivery of commercial ... consulting for the biotechnology corridor. With this expansion, KMK can better meet the ...
Breaking Biology News(10 mins):